Citations

Clear

590 citation(s) found for "Ho, Ben".

Correction: The complex genetics of gait speed: genome-wide meta-analysis approach
Ben-Avraham, Dan, Karasik, David , Verghese, Joe , Lunetta, Kathryn L. , Eicher, John D., Vered, Rotem, Deelen, Joris , Arnold, Alice M. , Buchman, Aron S. , Faul, Jessica D. , Nethander, Maria , Fornage, Myriam , Adams, Hieab H.H. , Matteini, Amy M., Callisaya, Michele L. , Smith, Albert V. , Yu, Lei, Jager, Philip L. De , Evans, Denis A., Guðnason, Vilmundur , Hofman, Albert , Pattie, Alison, Knopman, Davis S., Parimi, Neeta, Bandinelli, Stefania , Beekman, Marian , Gutman, Danielle , Sharvit, Lital , Mooijaart, Simon P. , Liewald, David C. , Houwing‐Duistermaat, Jeanine J. , Ohlsson, Claes , Moed, Matthijs, Hernandez, Dena, Thomson, Russell , Tranah, Gregory J. , Weir, David R. , Zhao, Wei , Starr, John M. , Johnson, Andrew D. , Bennett, David A. , Cummings, Steven R. , Deary, Ian J. , Harris, Tamara B., Kardia, Sharon L. R., Mosley, Thomas H. , Srikanth, Velandai , Windham, B. Gwen , Davies, Gail , Evans, Daniel S. , Ferrucci, Luigi , Atzmon, Gil , Bennett, David A. , Turner, Stephen T. , Smith, Jennifer A. , Tanaka, Toshiko , Corley, Janie , Launer, Lenore J. , Verlinden, Vincentius J.A. , Mellström, Dan , Geest, Jos N. van der , Karlsson, Magnus K , McWhirter, Rebekah , Liu, Ching‐Ti , Uitterlinden, André G. , Ikram, M. Arfan , Newman, Anne B. , Walston, Jeremy D , Slagboom, P. Eline , Kiel, Douglas P. , Murabito, Joanne M. , Adams, Hieab H H , Smith, Albert V , Ferrucci, Luigi , Ohlsson, Claes , Srikanth, Velandai K

Mayo Clinic

Aging | July 7, 2017 | Volume: 9 | Issue: 7 | Pages: 1844-1846

10.18632/aging.101260 | PMID 28696945 Get It

Factors associated with thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Rottenstreich, Amihai , Kalish, Yosef , Kleinstern, Geffen , Yaacov, Almog Ben, Dux, Joseph , Nissan, Aviram

Mayo Clinic

Journal of Surgical Oncology | June 26, 2017 | Volume: 116 | Issue: 7 | Pages: 914-920

10.1002/jso.24746 | PMID 28650573 Get It

Background and ObjectivesWe investigated the risk factors, incidence, and role of thromboprophylaxis in the development of thrombosis following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).MethodsWe reviewed data of patients with CRS/HIPEC in three hospitals.ResultsOverall, 192 patients underwent CRS/HIPEC during 2007‐2016. Mechanical (thigh‐length pneumatic compression stockings) and pharmacologic thromboprophylaxis (40 mg enoxaparin daily, starting 12 h before surgery until discharge) was provided for all patients; and 116 (60.4%) also received an extended course of enoxaparin for 2‐4 weeks after discharge. Twenty‐six patients experienced thrombotic complications (13.5%) including portal‐splenic‐mesenteric venous thrombosis (n = 11, 5.7%), pulmonary embolism (n = 10, 5.2%), and deep vein thrombosis (n = 5, 2.6%); most (n = 21, 80.8%) occurred after hospital discharge. Univariate analysis identified Peritoneal Cancer Index, intraoperative transfusion requirement, operative blood loss, operative time, lengths of hospital, and intensive care unit stay, and lack of administration of anticoagulation at discharge as significantly associated with thrombosis. With multivariate analysis, only the lack of anticoagulation therapy at discharge remained significantly associated with thrombosis (P = 0.0001).ConclusionsThromboembolic complications are common following CRS/HIPEC. As significantly lower rates of thrombosis were found in patients who received an extended course of anticoagulation, we support its use for at least 2 weeks after discharge.
Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas
Hardell, Elin, Josefson, Sofia, Ghaderi, Mehran , Skeie-Jensen, Tone, Westbom-Fremer, Sofia , Cheek, Elizabeth, Bell, Debra, Selling, Jonas, Schoolmeester, John K., Måsbäck, Anna , Davidson, Ben , Carlson, Joseph W. , Carlson, Joseph W

Mayo Clinic

American Journal of Surgical Pathology | June 15, 2017 | Volume: 41 | Issue: 9 | Pages: 1231-1237

10.1097/pas.0000000000000894 | PMID 28622181 Get It

Undifferentiated uterine sarcomas (UUS) are a heterogenous group of high-grade mesenchymal tumors. Although these tumors are highly aggressive, a subset of patients may experience long-term survival. These tumors have previously been divided morphologically into uniform and pleomorphic types. A previous study demonstrated that a mitotic index cutoff of 25 mitoses/10 high-power fields (corresponding to 11.16 mitotic figures/mm2) could successfully divide tumors into 2 prognostic groups with significantly different overall survival. The goals of the current study were to (1) validate this mitotic index cutoff in an independent, multicenter cohort and (2) explore the prognostic value of the mitotic index groups in relation to other clinicopathologic variables. Cases were included from 3 independent institutions: The Norwegian Radium Hospital, The Mayo Clinic, and Skåne University Hospital. A total of 40 tumors were included after central review. All cases were negative for the YWHAE-FAM22A/B and JAZF1-JJAZ1 translocations. Survival data were available on all patients. In this study, one-third of patients with UUS survived beyond 5 years. The crude (unadjusted) Cox Proportional Hazards model revealed a number of parameters that significantly impacted overall survival, including mitotic index group, patient age, stage, and the presence of tumor necrosis. Classification into the uniform and pleomorphic types was not prognostic. Combining these parameters into an adjusted model revealed that only the mitotic index group and stage were prognostic. On the basis of these findings, it is proposed that UUS be subdivided into “mitogenic” and “not otherwise specified” types.
Mild cognitive impairment as a risk factor for Parkinson's disease dementia
Hoogland, Jeroen , Boel, Judith A., Bie, Rob M.A. de , Geskus, Ronald B. , Schmand, Ben , Dalrymple‐Alford, John C. , Goldman, Jennifer G. , Tröster, Alexander I. , Burn, David J. , Geurtsen, Gert J. , Disease”, on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Rodríguez‐Oroz, María , Goldman, Jennifer G , Marras, Connie , Adler, Charles H. , Litvan, Irene , Disease”, on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Dalrymple-Alford, John C , de Bie, Rob M A , Geurtsen, Gert J

Mayo Clinic

Movement Disorders | June 12, 2017 | Volume: 32 | Issue: 7 | Pages: 1056-1065

10.1002/mds.27002 | PMID 28605056 Get It

ABSTRACT Background The International Parkinson and Movement Disorder Society criteria for mild cognitive impairment in PD were recently formulated. Objectives The aim of this international study was to evaluate the predictive validity of the comprehensive (level II) version of these criteria by assessment of their contribution to the hazard of PD dementia. Methods Individual patient data were selected from four separate studies on cognition in PD that provided information on demographics, motor examination, depression, neuropsychological examination suitable for application of level II criteria, and longitudinal follow‐up for conversion to dementia. Survival analysis evaluated the predictive value of level II criteria for cognitive decline toward dementia as expressed by the relative hazard of dementia. Results A total of 467 patients were included. The analyses showed a clear contribution of impairment according to level II mild cognitive impairment criteria, age, and severity of PD motor symptoms to the hazard of dementia. There was a trend of increasing hazard of dementia with declining neuropsychological performance. Conclusions This is the first large international study evaluating the predictive validity of level II mild cognitive impairment criteria for PD. The results showed a clear and unique contribution of classification according to level II criteria to the hazard of PD dementia. This finding supports their predictive validity and shows that they contribute important new information on the hazard of dementia, beyond known demographic and PD‐specific factors of influence. © 2017 International Parkinson and Movement Disorder Society
Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
Jones, Jeremy , Renfro, Lindsay A. , Al‐Shamsi, Humaid O. , Schrock, Alexa B. , Rankin, Andrew, Zhang, Ben Y., Kasi, Pashtoon Murtaza , Voss, Jesse S. , Leal, Alexis D. , Ali, Siraj M. , Kipp, Benjamin R. , Kopetz, Scott , Wolff, Robert A. , Jones, Jeremy C., Kasi, Pashtoon M, Sun, James, Ross, Jeffrey , Hubbard, Joleen M. , McWilliams, Robert R. , Jones, Jeremy C , Kasi, Pashtoon Murtaza , Sun, James X. , Ross, Jeffrey S , Grothey, Axel , Kopetz, Scott , Al-Shamsi, Humaid O

Mayo Clinic

Journal of Clinical Oncology | May 9, 2017 | Volume: 35 | Issue: 23 | Pages: 2624-2630

10.1200/jco.2016.71.4394 | PMID 28486044 Get It

Purpose Molecular diagnostic testing has become an integral part of the evaluation of patients with metastatic colorectal cancer (CRC). Expanded mutational testing, such as next-generation sequencing (NGS), often identifies mutations with unclear clinical or prognostic implications. One such example is BRAF mutations that occur outside of codon 600 (non-V600 BRAF mutations). Methods We conducted this multicenter, retrospective cohort study to characterize the clinical, pathologic, and survival implications of non-V600 BRAF mutations in metastatic CRC. We pooled patients in whom non-V600 BRAF mutations were identified from NGS databases at three large molecular genetics reference laboratories. Results A total of 9,643 patients with metastatic CRC underwent NGS testing. We identified 208 patients with non-V600 BRAF mutations, which occurred in 2.2% of all patients tested and accounted for 22% of all BRAF mutations identified. Cancers with non-V600 BRAF mutations, compared with cancers with V600E BRAF (V600E BRAF) mutations, were found in patients who were significantly younger (58 v 68 years, respectively), fewer female patients (46% v 65%, respectively), and patients who had fewer high-grade tumors (13% v 64%, respectively) or right-sided primary tumors (36% v 81%, respectively). Median overall survival was significantly longer in patients with non-V600 BRAF-mutant metastatic CRC compared with those with both V600E BRAF-mutant and wild-type BRAF metastatic CRC (60.7 v 11.4 v 43.0 months, respectively; P < .001). In multivariable analysis, non-V600 BRAF mutation was independently associated with improved overall survival (hazard ratio, 0.18; P < .001). Conclusion Non-V600 BRAF mutations occur in approximately 2.2% of patients with metastatic CRC and define a clinically distinct subtype of CRC with an excellent prognosis.
OS06.1 Genome-wide association study reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma
Melin, Beatrice , Kinnersley, Ben , Wrensch, Margaret , Jenkins, Robert B. , Ostrom, Quinn T. , Barnholtz‐Sloan, Jill S. , Houlston, Richard S. , Bondy, Melissa L.

Mayo Clinic

Neuro-Oncology | April 27, 2017 | Volume: 19 | Issue: suppl_3 | Pages: iii10-iii11

10.1093/neuonc/nox036.035 Get It

Automated T‐wave analysis can differentiate acquired QT prolongation from congenital long QT syndrome
Sugrue, Alan , Křemen, Václav , Bos, J. Martijn , Qiang, Bo , Rohatgi, Ram K., Sapir, Yehu , Brady, Peter A. , Asirvatham, Samuel J. , Friedman, Paul A. , Ackerman, Michael J. , Caraballo, Pedro J. , Noseworthy, Peter A. , Attia, Zachi I. , Asirvatham, Samuel J , Kremen, Vaclav , Bos, Johan M

Mayo Clinic

Annals of Noninvasive Electrocardiology | April 21, 2017 | Volume: 22 | Issue: 6 | Pages: No page available

10.1111/anec.12455 | PMID 28429460 Get It

BackgroundProlongation of the QT on the surface electrocardiogram can be due to either genetic or acquired causes. Distinguishing congenital long QT syndrome (LQTS) from acquired QT prolongation has important prognostic and management implications. We aimed to investigate if quantitative T‐wave analysis could provide a tool for the physician to differentiate between congenital and acquired QT prolongation.MethodsPatients were identified through an institution‐wide computer‐based QT screening system which alerts the physician if the QTc ≥ 500 ms. ECGs were retrospectively analyzed with an automated T‐wave analysis program. Congenital LQTS was compared in a 1:3 ratio to those with an identified acquired etiology for QT prolongation (electrolyte abnormality and/or prescription of known QT prolongation medications). Linear discriminant analysis was performed using 10‐fold cross‐validation to statistically test the selected features.ResultsThe 12‐lead ECG of 38 patients with congenital LQTS and 114 patients with drug‐induced and/or electrolyte‐mediated QT prolongation were analyzed. In lead V5, patients with acquired QT prolongation had a shallower T wave right slope (−2,322 vs. −3,593 mV/s), greater T‐peak‐Tend interval (109 vs. 92 ms), and smaller T wave center of gravity on the x axis (290 ms vs. 310 ms; p < .001). These features could distinguish congenital from acquired causes in 77% of cases (sensitivity 90%, specificity 58%).ConclusionT‐wave morphological analysis on lead V5 of the surface ECG could successfully differentiate congenital from acquired causes of QT prolongation.
Electroencephalography Predicts Poor and Good Outcomes After Cardiac Arrest: A Two-Center Study*
Rossetti, Andrea O. , Quiroga, Diego F. Tovar, Juan, Elsa , White, Roger D., Ben‐Hamouda, Nawfel , Oddo, Mauro , Nový, Jan , Britton, Jeffrey W. , Rabinstein, Alejandro A.

Mayo Clinic

Critical Care Medicine | April 13, 2017 | Volume: 45 | Issue: 7 | Pages: e674-e682

10.1097/ccm.0000000000002337 | PMID 28406812 Get It

Objective:The prognostic role of electroencephalography during and after targeted temperature management in postcardiac arrest patients, relatively to other predictors, is incompletely known. We assessed performances of electroencephalography during and after targeted temperature management toward good and poor outcomes, along with other recognized predictors.Design:Cohort study (April 2009 to March 2016).Setting:Two academic hospitals (Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Mayo Clinic, Rochester, MN).Patients:Consecutive comatose adults admitted after cardiac arrest, identified through prospective registries.Interventions:All patients were managed with targeted temperature management, receiving prespecified standardized clinical, neurophysiologic (particularly, electroencephalography during and after targeted temperature management), and biochemical evaluations.Measurements and Main Results:We assessed electroencephalography variables (reactivity, continuity, epileptiform features, and prespecified “benign” or “highly malignant” patterns based on the American Clinical Neurophysiology Society nomenclature) and other clinical, neurophysiologic (somatosensory-evoked potential), and biochemical prognosticators. Good outcome (Cerebral Performance Categories 1 and 2) and mortality predictions at 3 months were calculated. Among 357 patients, early electroencephalography reactivity and continuity and flexor or better motor reaction had greater than 70% positive predictive value for good outcome; reactivity (80.4%; 95% CI, 75.9–84.4%) and motor response (80.1%; 95% CI, 75.6–84.1%) had highest accuracy. Early benign electroencephalography heralded good outcome in 86.2% (95% CI, 79.8–91.1%). False positive rates for mortality were less than 5% for epileptiform or nonreactive early electroencephalography, nonreactive late electroencephalography, absent somatosensory-evoked potential, absent pupillary or corneal reflexes, presence of myoclonus, and neuron-specific enolase greater than 75 µg/L; accuracy was highest for early electroencephalography reactivity (86.6%; 95% CI, 82.6–90.0). Early highly malignant electroencephalography had an false positive rate of 1.5% with accuracy of 85.7% (95% CI, 81.7–89.2%).Conclusions:This study provides class III evidence that electroencephalography reactivity predicts both poor and good outcomes, and motor reaction good outcome after cardiac arrest. Electroencephalography reactivity seems to be the best discriminator between good and poor outcomes. Standardized electroencephalography interpretation seems to predict both conditions during and after targeted temperature management.
Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens
Loudig, Olivier , Ye, Kenny , Lin, Juan , Wang, Yihong , Ramnauth, Andrew, Stark, Azadeh , Chitale, Dhananjay , Greenlee, Robert T. , Multerer, Deborah, Honda, Stacey , Daida, Yihe G. , Glass, Andrew G., Rohan, Thomas E. , Ben‐Dov, Iddo Z. , Wang, Tao , Liu, Christina , Feigelson, Heather Spencer , Couch, Fergus J. , Wang, Yihong , Loudig, Olivier , Chitale, Dhananjay A

Mayo Clinic

International Journal of Molecular Sciences | March 14, 2017 | Volume: 18 | Issue: 3 | Pages: 627

10.3390/ijms18030627 | PMID 28335433 Get It

Formalin-fixed paraffin-embedded (FFPE) specimens, when used in conjunction with patient clinical data history, represent an invaluable resource for molecular studies of cancer. Even though nucleic acids extracted from archived FFPE tissues are degraded, their molecular analysis has become possible. In this study, we optimized a laboratory-based next-generation sequencing barcoded cDNA library preparation protocol for analysis of small RNAs recovered from archived FFPE tissues. Using matched fresh and FFPE specimens, we evaluated the robustness and reproducibility of our optimized approach, as well as its applicability to archived clinical specimens stored for up to 35 years. We then evaluated this cDNA library preparation protocol by performing a miRNA expression analysis of archived breast ductal carcinoma in situ (DCIS) specimens, selected for their relation to the risk of subsequent breast cancer development and obtained from six different institutions. Our analyses identified six miRNAs (miR-29a, miR-221, miR-375, miR-184, miR-363, miR-455-5p) differentially expressed between DCIS lesions from women who subsequently developed an invasive breast cancer (cases) and women who did not develop invasive breast cancer within the same time interval (control). Our thorough evaluation and application of this laboratory-based miRNA sequencing analysis indicates that the preparation of small RNA cDNA libraries can reliably be performed on older, archived, clinically-classified specimens.